GHIT FUND
ANNUAL REPORT 2016

LEAPS AND BOUNDS

Letter from Chair and CEO

As GHIT’s fifth anniversary approaches in 2017, our motivation to accelerate global health R&D is stronger than ever.
We extend our deepest gratitude to the development partners, funders, and sponsors whose creativity, courage, and passion fuel our own.

Kiyoshi Kurokawa, MD
Board Chair
BT Slingsby, MD, PhD, MPH
Chief Executive Officer

GHIT COMMITTED INVESTMENT

Leveraged

150
As of March 31, 2017

Our Pipeline

  • 12
    Preclinical

    Candidates
  • 6
    Clinical
    
Candidates
  • 2
    Proofs of Concept

    Achieved

GHIT INVESTED CLINICAL TRIALS

Six GHIT development partnerships have conducted successful clinical trials in Africa and South America.
As a result, and thesenumerous promising global health innovations are now firmly within reach.

DSM265
Disease: Malaria
Intervention: Drug
Development Stage: Phase IIa
Country: Peru
Project Detail >
E1224
Disease: Chagas disease
Intervention: Drug
Development Stage: Phase IIa
Country: Bolivia
Project Detail >
PZQ
Disease: Schistosomiasis
Intervention: Pediatric Drug
Development Stage: Phase IIb
Country: Ivory Coast
Project Detail >
DAR-901
Disease: Tuberculosis
Intervention: Vaccine
Development Stage: Phase IIb
Country: Tanzania
Project Detail >
BK-SE36/CpG
Disease: Malaria
Intervention: Vaccine
Development Stage: Phase Ib
Country: Burkina Faso
Project Detail >
(+)-SJ000557733
Disease: Malaria
Intervention: Drug
Development Stage: Phase IIa
Country: TBC
Project Detail >
(Since 2013)

EXPANDING GLOBAL NETWORK

  • 61
    Partnerships
  • 39
    Japanese Organizations
  • 49
    Non-Japanese Organizations
  • ADVANCING
    PORTFOLIO

  • ACCELERATING
    PARTNERSHIPS

  • ACCESS
    PRIORITIZED

  • ADVANCING PORTFOLIO

    We advance the global health R&D portfolio by investing in innovations that leverage Japan’s unparalleled resources and know-how, that can be brought to market in the relative near term, and that will have a significant impact on the global disease burden. We use private sector standards for our portfolio management.

    PDF Version of GHIT Annual Report 2016
    Learn More
  • ACCELERATING PARTNERSHIPS

    GHIT banks on a vibrant ecosystem of cross-sector, cross-border collaboration. Fostering that ecosystem is tremendously important to us. We are proud of the sectoral diversity of our development partnerships, which involve many research institutes, private companies, non-profit organizations, and academic institutions, all helping one another to achieve their respective project goals.

    PDF Version of GHIT Annual Report 2016
    Learn More
  • ACCESS PRIORITIZED

    Today, over two billion people lack access to essential medicines. In the poorest parts of Africa and Asia, which bear the brunt of the global infectious disease burden, this figure rises to half of the population. For GHIT, and all its partners, access is inextricably linked to the R&D process.

    PDF Version of GHIT Annual Report 2016
    Learn More